Phaseline

Companies › Pharmosa Biopharm

Pharmosa Biopharm: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
L608 Liposomal inhalation suspension–Phase 1Healthy Adult ParticipantsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06429930L608 Liposomal inhalation suspensionPhase 1Healthy Adult ParticipantsCardiovascularDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.